Increased adiposity is a current concern in people living with HIV treated with the last-generation antiretroviral drugs of the integrase inhibitor family. The platform NAM-AIDSMAP, devoted to provision of independent, accurate & accessible information about HIV, highlights our findings recently published in Life Sciences (doi: 10.1016/j.lfs.2022.120948). We showed that the integrase inhibitor dolutegravir suppresses the production of adiponectin, a chemical secreted by fat tissue that regulates insulin sensitivity, which provides further evidence that dolutegravir can have direct effects on the human cells that store fat (see https://www.aidsmap.com/news/oct-2022/dolutegravir-has-direct-effects-fat-cells).
Francesc Villarroya, as invited speaker, Tania Quesada, through a selected communication, and Moisès Castellà through a poster communication, presented our current research on inter-organ singaling and molecular actors involved in metabolism and adipose tissue thermogenic plasticity at the EMBO meeting held in Málaga last 3 to 6 October.
García-Beltran C, Cereijo R, Quesada-López T, Malpique R, López-Bermejo A, de Zegher F, Ibáñez L, Villarroya F.
BMJ Open Diabetes Res Care. 2020 Feb;8(1):e001035.
Circulating growth-and-differentiation factor-15 in early life: relation to prenatal and postnatal growth and adiposity measurements.
Díaz M, Campderrós L, Guimaraes MP, López-Bermejo A, de Zegher F, Villarroya F, Ibáñez L.
Pediatr Res. 2020 Apr;87(5):897-902.
Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy.
Dominguez-Gonzalez C, Badosa C, Madruga-Garrido M, Martí I, Paradas C, Ortez C, Diaz-Manera J, Berardo A, Alonso-Pérez J, Trifunov S, Cuadras D, Kalko SG, Blázquez-Bermejo C, Cámara Y, Martí R, Mavillard F, Martin MA, Montoya J, Ruiz-Pesini E, Villarroya J, Montero R, Villarroya F, Artuch R, Hirano M, Nascimento A, Jimenez-Mallebrera C.
Sci Rep. 2020 Jun 22;10(1):10111.
Malpique R, Gallego-Escuredo JM, Sebastiani G, Villarroya J, López-Bermejo A, de Zegher F, Villarroya F, Ibáñez L.
Int J Obes (Lond). 2019 Feb;43(2):384-391.
ICREA Academia Awards are given for a period of five years in recognition of an excellent scientific trajectory of university professors. Awardees receive funds over this period to support their lines of research,e ICRE teaching activities and allow awardee to focus on research activity.
The Integrase Strand Transfer Inhibitor (INSTI) antiretrovirals are among the last generation drugs to treat HIV-infected patients. Recent data indicate that these patients show abnormally increased adiposity after treatment. Thus, the HIV infection and global obesity epidemics meet to confer to HIV patients increased metabolic and cardiovascular comorbidities.The coordinated research projects will assess the molecular and cellular basis of such phenomenon and will identify potential targets of preventive intervention.
That system, in which bradykinin is a main actor, has been traditionally associated with the physiology of the renal and cardiovascular systems and processes of inflammation and pain. Our study, led by Dr.M.Peyrou, Juan de la Cierva researcher at our lab, reports that the kallikrein-kinin system acts as mechanism of molecular self-control of brown and beige adipose tissue thermogenic activation, and could help prevent the harmful effects of excessive activation of brown adipose tissue occurring in some pathological conditions such as cachexia or recovery from severe burns.The full article is accessible at: https://rdcu.be/b3Ud4